Funding
We are thankful to our funding agencies for their support:
Baden Württemberg Stiftung
REsolvInG ImmuNITy to targEt Brain Tumors (RE-IGNITE). 2020 - 2023
Deutsche Krebshilfe
A MultIceNTer PhasE I RNA VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas – (INTERCEPT H3). 2019 - 2023
Deutsches Konsortium für Translationale Krebsforschung
TCR Proof of Concept in cooperation with NCT (TCR-POC)
AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial (AMPLIFY-NEOVAC, NOA-21)
CAR2Brain_Immune Response CAR-NK Immunotherapy in Glioblastoma_DKTK Joint Funding “UPGRADE”. 2020 - 2024
Deutsche Forschungsgemeinschaft - CRC 1366
© dkfz.de
Vascular control of tumor immunity in the CNS. CRC1366. 2019 - 2022
Deutsche Forschungsgemeinschaft - CRC UNITE 1389
Understanding and targeting resistance in glioblastoma. CRC UNITE 1389. 2019 - 2023
Deutsche Forschungsgemeinschaft - RTG 2099
© dkfz.de
Hallmarks of Skin Cancer, Tumor Microenvironment and Melanoma Immunity, Response and Resistance to Checkpoint Blockade in melanoma brain metastases. CRC RTG2099. 2019 - 2024
Deutsche Forschungsgemeinschaft - GRK 2727/1
© dkfz.de
InCheck „Innate Immune Checkpoints in Cancer and Tissue Damage"
DKFZ-MOST
The role of CXCL10 in the immune regulation of melanoma and glioma. 2019 - 2022
Hertie Stiftung
Hertie Academy of clinical neuroscience als Kristallisationspunkt für ein Hertie Network of Excellence in clinical neuriscience. 2019 - 2022
Swiss Cancer League, the Swiss Cancer Research foundation and the Union for International Cancer Control (UICC)
Swiss Bridge Award 2019 - T cell receptor transgenic cellular therapies targeting shared T helper cell neoepitopes in brain tumors. 2019 - 2022